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Abstract
Background Chronic obstructive pulmonary disease
(COPD) is a progressive and irreversible disease responsible
for the deaths of 3 million people worldwide in 2005, and
predicted to be the third leading cause of death worldwide by
2030. Many COPD models developed to date have followed
a Markov structure, in which patients or populations can
move between defined health states over successive time
periods or cycles. In COPD, health states are typically based
on disease severity defined solely by lung function, as
described by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines. These current modelling
methods may restrict the ability to reflect the disease pro-
gression/clinical pathway or clinical practice.
Objectives Given these limitations in previous COPD
models, the authors aimed to develop a more flexible model
that could improve on the description of the clinical disease
pathway. The overall objective of this model was to inform
the development of policies, guidelines or cost-effectiveness
analyses. A second objective was to validate the model in
relation to existing epidemiology studies of COPD.
Methods A patient simulation model was developed in
Microsoft ExcelTM. The predictability of the model was
tested by populating it with data from natural history of
disease studies as well as with clinical trial data. Each
patient moves through the model with demographic char-
acteristics randomly generated from a set distribution.
These characteristics determine the risk of clinical events
occurring in the model.
Results The validation with these studies found the model
to have generally good predictive ability, yielding in this
way a good degree of external validity.
Conclusions The micro-simulation model is a flexible
approach for modelling COPD that allows consideration of
complex COPD treatment pathways. The model was found
to be generally robust in terms of predicting clinical out-
comes of published studies when tested against other
studies. It has significant potential as a tool for supporting
future COPD treatment positioning decisions as well as to
inform the development of policies, guidelines or cost-
effectiveness analyses.
Key Points for Decision Makers
• This new model offers flexibility in simulating complex
chronic obstructive pulmonary disease (COPD) treat-
ment pathways
• The model clinical predictability was validated using
published COPD studies and found to be acceptable
• Treatment switching following specific events is a key
functionality of the model
• This model has potential as a tool for supporting future
COPD treatment positioning decisions as well as to
inform the development of policies, guidelines or cost-
effectiveness analyses
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Chronic obstructive pulmonary disease (COPD) is a pro-
gressive and irreversible disease predicted to be the third
leading cause of death worldwide by 2030 [1]. COPD is
caused by the inhalation of noxious gases including ciga-
rette smoke in combination with host factors and is asso-
ciated with limitation of airflow symptoms such as
breathlessness and cough, as well as poor health-related
quality of life (HR-QOL) [2]. A subset of COPD patients is
also susceptible to exacerbations, which may require a
change in maintenance medication, provision of emergency
treatment or a hospital inpatient stay. COPD results in a
social and economic burden to society and often impacts in
later working life [3]. Current clinical guidelines for COPD
indicate a standard treatment pathway according to disease
progression [2, 4]. The treatment options available nowa-
days are increasing with inhaled therapies, alone or in
combination, having a preponderant role. A thorough
understanding of treatment sequences and therapy combi-
nations is therefore essential when considering the best
treatment choice for a COPD patient. However, given the
current scarcity of resources in most healthcare systems, it
is also imperative that the treatment options are value for
money (cost effective) for the payers.
When examining the published literature on the cost
effectiveness of COPD treatments, the majority of studies
identified perform pharmacoeconomic evaluations along-
side clinical trials, using effectiveness and cost data collected
prospectively over the course of the trial [5, 6]. In a sys-
tematic review published in 2008, ten out of the 15 studies
identified were evaluations alongside clinical trials and five
were based on economic models [6]. While randomized
controlled trials (RCTs) are considered the gold standard for
the evaluation of clinical efficacy [7], the generalizability of
an economic evaluation alongside an RCT to real-life clin-
ical practice may be limited due to the choice of comparator
and the availability of data over a long period of time (i.e.
study duration). Buxton et al. [8] discuss the limitations of
trial-based evaluation versus the dangers of modelling but
acknowledge that models allow for the extrapolation of data
when only short-term data exist, the linking of intermediate
trial endpoints to long-term outcomes of interest to the payer,
making adjustment to make the evaluation more generaliz-
able to other settings, and the incorporation of other com-
parator data not included in trials. Economic models are
useful alternatives when RCTs do not provide all the infor-
mation necessary; however, models should endeavour to be
as simple as possible while still meeting the stated objective.
Some economic evaluations have used models with
observational data incorporated into them to increase the
applicability to the real world [9]; however, the choice of
model structure also imposes limitations on how the data
can be used and therefore on the generalizability of the
model to clinical practice.
Most of the COPD models to date follow a Markov
structure, in which patients or populations can move
between defined health states over successive time periods or
cycles [6, 10]. In COPD, health states are typically based on
disease severity defined solely by lung function, as described
by the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) guidelines [2]. These current modelling
methods may restrict the ability to reflect the disease pro-
gression/clinical pathway or clinical practice. This is related
firstly to the memory-less nature of Markov modelling and
secondly to the necessity to construct discrete health states
for each event or combination of events if it impacts the
expected pay-off in a meaningful way. Markov models do
not have the ability to retain memory of a patient’s previous
health states without the introduction of additional health
states or tunnel states [11]. Most models currently lack the
ability to describe a change in treatment [12–16], that is, a
treatment switch or re-initiation of therapy for a patient who
has discontinued therapy without the addition of more health
states to describe what should be a similar clinical pathway
but with slightly different risks of clinical events occurring.
Moreover, designing a model with more complex treatment
pathways may encounter a lack of appropriate data on
transition probabilities between health states and costs.
Defining health states based on GOLD criteria is also often
problematic as several clinical studies [17, 18] base their
endpoint measurements on pre-bronchodilator measure-
ments, rather than post-bronchodilator measurements as
prescribed by GOLD once past the screening stage; this
limits the applicability of these data in a model.
Some studies have looked at alternative ways to model
COPD. The most common of these is to apply regression
techniques to predict the occurrence of specific clinical
events that are significant. In the case of COPD, exacer-
bations are clear candidates for such an event due to their
cost and impact on patient quality of life (QOL). Aaron
et al. [19] and Mapel et al. [20] have both developed such
methods allowing for the prediction of recurrent exacer-
bations. Mapel et al. [20] go one step further to apply the
regression model to the context of an economic evaluation,
arguing that the modelling of exacerbation data based on
the healthcare utilization data is sufficient for cost-effec-
tiveness analyses. Treatments that reduce the risk or
severity of an exacerbation are likely to be shown to be cost
effective, given the significant cost of treating a severe
exacerbation. However, such a regression model does not
take into account other events that may be impacted by
treatment, such as lung function decline or impact on
symptoms such as dyspnoea.
With these previous limitations in mind, the authors
have developed an economic model incorporating micro-
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simulation techniques that will allow modelling a single
patient at a time, generating clinical events and treatment
switches according to preset probabilities and triggers. This
type of model allows for the occurrence of any number of
events such as exacerbations, decline in lung function,
worsening of dyspnoea (as measured by clinical instru-
ments) and improvement in QOL (as measured by disease-
specific or generic instruments). Following the taxonomy
described by Brennan et al. [21], this model may be con-
sidered an individual sampling model (ISM) that simulates
each individual through discrete time periods. The major
difference to previous COPD models is the absence of
defined health states per se. Outcomes are estimated on the
basis of the presence/absence of events and lung function
levels modelled as a continuous variable. These changes
increase the flexibility with which to describe the different
combinations of clinical events that can be experienced by
a patient over the course of their disease. GOLD state
definitions are assigned whenever estimating outcomes that
are related to disease severity, but there is potential to
avoid using these state definitions if outcomes and pay-offs
can be estimated independently of GOLD disease severity.
2 Objectives
The objective of this study was to develop a COPD model
incorporating simulation techniques in an attempt to
address the limitations mentioned in Sect. 1, with the
purpose of informing the development of policies, guide-
lines or cost-effectiveness analyses. A second objective
was to validate the model in relation to existing epidemi-
ology studies of COPD.
3 Methods
3.1 Model Structure
This simulation-based model combines information
derived from the natural history of COPD studies, clinical
data and costs. The model is built in Microsoft ExcelTM
and follows a patient according to any predefined time
horizon, set by default to lifetime to capture all relevant
outcomes. The patient progresses through the model using
Monte Carlo simulation methods at each cycle. A disease
severity level is assigned at each cycle to estimate the
probabilities of certain clinical outcomes. The disease
severity will also influence some of the model’s pay-offs
such as HR-QOL and costs.
The clinical profile (baseline characteristics) of a patient
at the start of the model will have a determinant impact on
the final outcomes of the model as these will determine the
disease severity group in which the patient belongs at the
start and in subsequent cycles by applying a rate of decline
in lung function. The GOLD disease severity classification
was used as it is current practice to collect this information
in clinical trials and most other outcomes are presented in
the literature by these disease severity levels. However, as
stated earlier, if outcomes and pay-offs can be estimated
without reference to GOLD disease severity, the need for
assigning GOLD states becomes unnecessary.
In order to determine the lung function of a patient at the
start of the model, some of the baseline patient character-
istics are assumed to be correlated. In order to understand
and quantify the correlation between these baseline char-
acteristics, patient-level data from three multinational,
multi-centre, randomized, double-blind, placebo-controlled
studies evaluating the efficacy of indacaterol in over 3,800
patients with moderate to severe COPD were made avail-
able [22–24]. A correlation matrix was constructed
employing the Cholesky decomposition method on this
pooled dataset [25]. The distribution of each individual
variable was tested and all continuous variables were found
to be Normally distributed. The following variables were
regressed against each other to test for correlations: forced
expiratory volume in 1 second (FEV1)% predicted, age,
gender, height and smoking status. The co-variance matrix
linked gender and age to height, smoking status and lung
function in order to generate the FEV1 value at the start of
each simulation for each patient.
The generated patient progresses through the model and
experiences clinical events according to preset probabili-
ties. The model employs Monte Carlo simulation methods
to follow a patient through the model as dictated by
probabilities of developing complications, being symp-
tomatic or progressing, taking into account his, or her,
current treatment status. These include the rate of FEV1
decline, the exacerbation rate, the discontinuation rate, and
changes in Baseline and Transition Dyspnoea Index (BDI-
TDI) and the St. George’s Respiratory Questionnaire
(SGRQ) scores. These clinical events may trigger a treat-
ment switch, which can be specified at the start of the
analysis by the user to a maximum of three criteria. For
example, the user can specify a treatment switch after the
patient has experienced two exacerbations over the course
of the last year.
Progression through the model is captured in discrete
cycles, the length of which may be adjusted by the user.
Events are generated in a hierarchical fashion such that a
patient is first tested against a probability of death, fol-
lowed by discontinuation of treatment. Smoking status (i.e.
smoker, intermittent smoker or ex-smoker) determines
current level of lung function, which in turn determines the
probabilities of experiencing exacerbations and changes in
other measures.
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Analyses are run in cohorts of patients and both the
number of patients per cohort and the number of cohorts
evaluated are determined by the user. Figure 1 describes
the model in a schematic diagram.
3.2 Model Parameters
3.2.1 Time Horizon and Discounting
The model is designed to use any cycle length as long as it
is defined in monthly units. The user has the possibility of
setting both the cycle length and the time horizon as nee-
ded. For time horizons longer than 1 year, the user can
define discount rates for benefits and costs, which can be
selected as appropriate for the base-case analysis, sensi-
tivity analyses or to comply with different local
recommendations.
3.2.2 Number of Patients and Number of Cohorts
The default settings are defined as 1,000 patients for each
of 500 cohorts: these values were selected for robustness
and accuracy of the results, but can be changed by the
user.
3.2.3 Interventions
The initial treatment received by the patient is chosen by
the user. The treatment can be compared with an alterna-
tive treatment, placebo or a ‘no treatment’ option. All other
treatments switches, including discontinuations, will be
determined by patient symptoms as manifested by events.
This decision rule can be set by the user in terms of
defining the numbers of events and treatment choices fol-
lowing the fulfilment of those criteria. Withdrawal rates
can also be specified by the user according to the data
available or assumptions.
3.3 Model Inputs
3.3.1 Lung Function Improvement
As mentioned in Sect. 3.1, FEV1 level at baseline is
determined via a co-variance matrix. The initial treatment
effect is specified by the user according to data availability
or assumptions. Default settings are based on improvement
in FEV1 observed in the indacaterol phase III trials
[22–24]; other RCT sources or meta-analyses may also be
considered as a data source for this input. Data available
from published studies were used in the validation process
 Cohort-level input 
Average age, height, 
gender and smoking 
status 
Patient generation 
Age, height, gender 
and smoking status 
Event generation 
according to treatment 


















Fig. 1 Model schematic. FEV1 forced expiratory volume in 1 second, SGRQ St. George’s Respiratory Questionnaire, TDI Transition Dyspnoea
Index
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[17, 18, 26, 36]. Patients who discontinued treatment lose
the benefit experienced by falling back to the expected
level of FEV1 as if the patient had remained untreated.
FEV1 declines at every cycle are set by default with
known epidemiological data from the Lung Health Study
[26]. However, the user is able to change the FEV1 rate
of decline, again according to data availability or
assumptions.
3.3.2 Exacerbations
A non-severe exacerbation in the model was described as
one where the patient has had contact with a healthcare
provider. A severe exacerbation was defined as any exac-
erbation requiring hospitalization. Mild exacerbations
managed by patients were not included in the model.
Probabilities of exacerbation are determined by severity of
disease and treatment choice. Ratios of exacerbation rates
were based on the indacaterol phase III trials as a default
[22–24] or from published data when available (e.g.
UPLIFT [Understanding Potential Long-term Impacts on
Function with Tiotropium] [18]). Conservative assump-
tions were made when comparative data were not known.
Disease severity is determined by FEV1 status as described
by the GOLD guidelines. Exacerbations—either severe or
non-severe—are defined in annual rates, which in turn are
adjusted to the specified cycle length. The treatment choice
informs the rate ratio that should be applied to the baseline
rate to reflect the treatment effect of each intervention.
3.3.3 Mortality
Probabilities of death are determined by severity of disease
[27] and general all-cause mortality. The mortality rates
(Table 1) are defined as ‘excess’ mortality rates found for
COPD patients in The Netherlands and may include other
smoking-related causes of death [27]. The probabilities of
death presented here are annual and get adjusted to the
model cycle length. There is research that suggests that
determinants of death in COPD patients may also be found
in other clinical indices (i.e. other than COPD disease
severity indices), but this requires further research [28].
Another source of COPD excess mortality was available,
also by GOLD disease severity, which indicated a much
lower overall mortality rate [30]. Both sources were tested
and both were found to have limitations but Hoogendoorn’s
data [27] are used as default and are presented in Table 1.
General all-cause mortality data were derived using UK
interim life tables from the Office of National Statistics
[29]. These can also be adapted according to the user data
or setting.
3.3.4 Transition Dyspnoea Index
Dyspnoea is a primary symptom of COPD and has been
defined as an uncomfortable awareness of breathing or an
increased respiratory effort [31]. The Transition Dyspnoea
Index (TDI) is an instrument used to assess breathlessness
and the impact of an intervention [32].
TDI scores are dependent on treatment and on the period
of time on each treatment. A change in TDI can be selected
as a trigger for switching treatment. The baseline
assumption is that one unit decline in TDI is clinically
significant and will result in a switch of patient medication.
3.3.5 Health-Related Quality of Life
HR-QOL is assessed using both generic and COPD-spe-
cific measures. Health status is represented by a specific
measure of HR-QOL: the SGRQ. The SGRQ is designed to
measure health impairment in patients with asthma and
COPD [33]. From a clinical point of view, a significant
change in health status can lead to treatment switching. The
user can therefore select a change in SGRQ as a criterion
for switching in the Control sheet. It was assumed that a
worsening of four units in SGRQ (i.e. ?4, since the higher
the SGRQ, the worse the health status) can trigger a change
in patient medication. SGRQ scores increase with time and
this was reflected in the current assumptions.
The model is also designed to be populated with generic
measures of HR-QOL such as utilities based on the EQ-5D
or the SF-6D. Baseline utilities associated with each dis-
ease severity state are applied at each cycle. Whenever a
patient experiences an exacerbation, a utility decrement is
subtracted from the baseline utility value corresponding to
the cycle where the event had occurred. An algorithm that
predicts EQ-5D utility from the SGRQ was recently
developed [34] to allow the use of utilities from the SGRQ.
3.3.6 Costs
Costs of drugs, exacerbations and maintenance are set by
the user according to the setting of interest. In each cycle,
the cost of maintenance is determined by disease severity.
Exacerbation costs are added if a patient experiences an
exacerbation episode within that cycle. It is assumed that





Mild (stage I) 2.25
Moderate (stage II) 3.56
Severe (stage III) 5.42
Very severe (stage IV) 7.74
GOLD Global Initiative for Chronic Obstructive Lung Disease
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there are no other costs associated with symptoms occur-
ring to patients. The model adopts the healthcare payer’s
perspective, therefore indirect costs are not considered.
3.4 Model Outputs
The model produces three sets of outputs: clinical, cost and
cost effectiveness. These will help to inform decisions
regarding the adoption of competing interventions by
healthcare payers. Although these decisions are not based
on cost-effectiveness criteria only, an intervention is con-
sidered to be cost effective when the incremental cost-
effectiveness ratio is below a predefined accepted threshold
representing the willingness to pay by the healthcare payer.
This threshold is usually defined as a cost per measure of
effectiveness. The decision rules for economic evaluation
are described elsewhere [35].
A summary of model inputs and outputs is available in
Table 2.
3.4.1 Uncertainty
In order to characterize parameter uncertainty (or second-
order uncertainty), probability distributions were fitted to
some of the model’s inputs. Gamma distributions were
fitted to treatment efficacy (initial FEV1 boost) and to cost
parameters; a log-Normal distribution was fitted to exac-
erbation parameters; and, finally, Beta distributions were
fitted to utilities, withdrawals and mortality. The merits of
assigning these distributions to some of the model’s
parameters are described elsewhere [25]. Ninety-five
percent confidence intervals (CIs) are presented around the
results to represent this uncertainty. This also allows for the
development of cost-effectiveness acceptability curves
(CEAC) but the current software format emphasizes
transparency rather than speed of computations; therefore,
the inclusion of a sufficient number of iterations would
require a correspondingly large amount of time.
3.4.2 Model Validation
The model was subjected to a comprehensive validation
process. Firstly, it was tested to ensure that all mathematical
calculations were accurate and consistent with its specifi-
cations. Secondly, the model was tested by being populated
with four datasets, three of which were from clinical trials
[17, 18, 26] and one a natural history of disease study [36].
Our aim was to assess if the model was able to replicate the
results of these studies with an acceptable degree of accu-
racy, ensuring internal and external validity. Table 3 shows
the inputs extracted from the four published studies used to
assess the model validity [17, 18, 26, 36].
The parameters tested varied by the availability of
information in each publication, but focused on clinical
parameters such as mortality and exacerbation rates, as
well as FEV1 decline. The model benefited from the clin-
ical and methodological scrutiny of key opinion leaders in
order to ensure not only that the model was consistent and
coherent with the clinical pathway of COPD but also to
certify that the methods used were robust. For the valida-
tion exercise, the micro-simulation model was run for 500
patients and 50 cohorts.
Table 2 Summary of the
model’s inputs and outputs
FEV1 forced expiratory volume
in 1 second, HR-QOL health-
related quality of life, ICER
incremental cost-effectiveness
ratio, ICUR incremental cost-
utility ratio, NA not applicable,


















Number of cohorts to be
run




Average SGRQ score in
each arm
Mean difference of FEV1
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4 Results
The results of the model obtained by simulating the four
studies subsequently are presented in this section.
4.1 UPLIFT
UPLIFT is the longest running and largest RCT to date in a
COPD population [18]. It compared 4 years of therapy
with either tiotropium or placebo in moderate to very
severe patients with COPD. The primary endpoints were
the rate of decline in the mean FEV1 before and after
bronchodilation beginning on day 30. Secondary endpoints
included measures of forced vital capacity (FVC), changes
in response on SGRQ, exacerbations of COPD and mor-
tality [18].
The co-variance matrix in the model predicted accu-
rately the smoking status of the patients, although CIs were
not available for comparison in the original publication
[18] (Table 4). Estimates of relative risk (RR) of exacer-
bations from the model fell within the CI of the study. The
model overestimated the annual FEV1 decline rate, which
could be attributed to the fact that around 10 % of the
UPLIFT trial population were very severe patients. This
group typically has a lower rate of decline than patients in
other GOLD stages.1 The estimated mortality RR fell
within the CI of the published results [18], but the absolute
rates of both arms are slightly overestimated. Treatment
benefit in mortality is not as well captured when using
mortality rates associated with GOLD states, as this only
allows for a difference in mortality rate when the lung
function improves sufficiently for a GOLD state change.
Alternative possibilities include mapping the change in
mortality risk directly to other clinical indicators, such as
lung function decline or change in TDI, or related to
exacerbations, which could be made possible with suffi-
ciently long-term data analysed at the patient level.
4.2 Lung Health Study
The Lung Health Study was a clinical trial that assessed the
benefits of smoking cessation over a time horizon of
5 years [26].
Table 3 Value input of studies used in the validation process
Variable UPLIFT [18] Lung Health Study [26] TORCH [17] OLIN [36]
Mean ± SD age at baseline (years) 64.5 ± 8.4 48.5 ± 6.8a 65 ± 8.2 56.8 ± 10.7b
Cycle length (months) 6 12 6 12
Time horizonc (years) 4 5 3 20
Treatments Tiotropium vs. PL NA Salmeterol/fluticasone vs. PL NA
Males (%) 75 63.85 75 64
Mean FEV1 vs. PL (ml) 56
d NA 75e NA
FEV1% of predicted NA 78 NA 70.7












RR of exacerbations vs. PL 0.86 NA NA NA
Smokers (%) NA NA 43 NA
Withdrawal per cycle (%) NA NA Salmeterol/fluticasone pts: 5.6
PL pts: 7.3
NA
FEV1 forced expiratory volume in 1 second, GOLD Global Initiative for Chronic Obstructive Lung Disease, NA not available, PL placebo,
pts patients, RR relative risk, SD standard deviation
a The SD is estimated from available sub-group data [26]
b The mean age and SD are estimated from available age intervals [36]
c Equivalent to study duration
d The mean absolute improvement in FEV1 was determined by the average of the mean improvements from both groups: 47–65 ml after
bronchodilation [18]
e The mean FEV1 improvement was estimated from the graph in the publication [17]
1 The baseline population considered in our analysis included mainly
moderate to severe COPD patients.
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The model was built originally with active treatment
arms and a placebo arm only. When this validation was
conducted using the Lung Health Study, it was observed
that the modelled annual mean rate of FEV1 decline was
overestimated. This was attributed to an initial FEV1
boost in the placebo arm based on clinical trial data [18,
22], which cause patients discontinuing from placebo to
have a significant drop in their FEV1 in line with the
assumption described in Sect. 3.3.1 of loss of treatment
benefit upon treatment termination. In order to address
this paradigm, a no treatment arm was added where it was
assumed no initial benefit in FEV1 would be observed and
patients would only be subject to a constant rate of FEV1
decline.
The model was re-run and it was observed that the mean
rates of decline obtained after running the model were
aligned with mean rates of decline published by Scanlon
et al. [26], which highlights that the inclusion of a no
treatment arm is appropriate and it is correctly used in the
model (61.54 ml/year in smokers and 31.22 ml/year in
ex-smokers obtained from the model vs. 62 ml/year in
smokers and 31 ml/year in ex-smokers from the study
publication [26]). These rates are used in the base case of
the model and are not affected when no treatment is
selected.
4.3 TORCH
TORCH (TOwards a Revolution in COPD Health) was a
randomized, double-blind, placebo-controlled trial where
salmeterol and fluticasone in combination was compared
with placebo in moderate to very severe COPD patients
[17]. The length of follow-up was 3 years and the primary
endpoint was death from any cause. Secondary endpoints
included frequency of exacerbations, health status using the
SGRQ and spirometric values [17].
The correlation matrix was broken to allow for a higher
proportion of smokers as this had an impact on the rate of
FEV1 decline. Table 5 shows the results obtained in the
model when implementing the TORCH trial data [17].
The RRs of experiencing an exacerbation are compa-
rable between the model and the trial publication [17] (i.e.
0.72 vs. 0.75, respectively). However, absolute rates
observed in the model were slightly lower than those
reported in the publication [17]. This could be due to the
baseline rate of exacerbations in the source indacaterol
trials [22–24] being extremely low, and could be adjusted
with other data sources.
The average mean change of FEV1 over the model time
horizon (3 years) was smaller than that reported in the
study [17]. This difference can be explained by the trial
Table 4 Results of external validation with UPLIFT [18]
Key results Published results [18] Model results
Smoking status [% of current smokers (95 % CI)] 29 (CI unpublished) 29.35 (28.76–29.94)
RR of exacerbations per patient-year
of tiotropium vs. PL (95 % CI)
0.86 (0.81–0.91)
Leading to hospitalization: 0.94 (0.82–1.07)
0.85 (0.84–0.85)
Leading to hospitalization: 0.84 (0.82–0.85)
Annual FEV1 decline [ml] Tiotropium (± SE): 40 (±1)
PL (± SE): 42 ml (±1)
Tiotropium: 44.3 (95 % CI 44.0–44.6)
PL: 43.2 (95 % CI 42.8–43.5)
Mortality Tiotropium: 14.4 %
PL: 16.3 %
RR 0.87 (95 % CI 0.76–0.99)
Tiotropium: 17.63 %
PL: 17.92 %
RR 0.98 (95 % CI 0.98–0.99)
CI confidence interval, FEV1 forced expiratory volume in 1 second, PL placebo, RR relative risk
Table 5 Results of external validation with TORCH [17]
Key results Published results [17] Model results




Annual rate of exacerbations per patient Combination: 0.85
PL: 1.13
RR 0.75 (95 % CI 0.69–0.81)
Combination: 0.74
PL: 1.05
RR 0.71 (95 % CI 0.709–0.710)
Adjusted mean change in FEV1 averaged over 3 years
of combination therapy vs. PL [litre (95 % CI)]
0.092 (0.075–0.108); p \ 0.001 0.067 (0.064–0.069)
Adjusted mean change in SGRQ score averaged over
3 years [units (95 % CI)]
Combination: -3.0
PL: ?0.2
Combination: -2.10 (-2.08 to -2.12)
PL: -1.54 (-1.53 to -1.54)
CI confidence interval, FEV1 forced expiratory volume in 1 second, PL placebo, RR relative risk, SGRQ St. George’s Respiratory Questionnaire
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patients receiving placebo experiencing a negligible FEV1
improvement.2 However, this value was not adjusted for
placebo patients in the model, who were given a 130 ml
improvement in their first cycle. This led to an increase in
FEV1 change between the comparators in TORCH [17]
compared to that observed in the model. Although possible,
the use of the no treatment arm in the model was not
considered appropriate given that the TORCH trial uses
placebo as a comparator.
The mortality rates obtained in the model were higher
than those in the published data [17]. Distribution of
GOLD states in the TORCH study was not available, but
the mean FEV1% predicted in the population was 44 %,
higher than the mean in UPLIFT of 39 %, indicating a
slightly less severe population than UPLIFT [17, 18]. The
current data source for mortality used may overestimate
mortality rates associated with the milder health states, but
the use of the alternative data source significantly under-
estimated overall mortality. Further research that correlates
different clinical indices and patient characteristics, such as
age and smoking status, should improve the accuracy of
mortality rates specific to COPD patients.
SGRQ results are the most disparate between the model
and the study. Change in HR-QOL over time is not well
documented in literature. Change in SGRQ is usually
reported over short periods of time, which makes long-term
extrapolation of change in SGRQ difficult. Studies utilizing
registry data or similar observational studies over the long
term may be able to significantly improve the accuracy of
SGRQ outputs.
4.4 OLIN
OLIN (Obstructive Lung Disease in Northern Sweden) was
a longitudinal study that followed COPD patients (64 %
male) over 20 years [36]. The primary endpoint was mor-
tality and the secondary endpoint was the annual decline in
FEV1 among survivors [36].
The correlation matrix was not used to generate patients
for this simulation in order to use the published FEV1%
predicted of the patient population [36], which was
significantly higher than the original indacaterol trials
[22–24].
The modelled proportion of patients who have died
appears to be overestimated when compared with the
average mortality rate reported in the study (70 % [95 %
CI 69.61–70.69] as a model result vs. 54 % as reported in
the publication [36]). The OLIN study cohort has consid-
erably less severe disease than those in the indacaterol
studies [22–24], UPLIFT [18] or TORCH [17] and bears
out the hypothesis that the current data source overesti-
mates the mortality rates associated with the less severe
disease states. This is especially likely for the mild disease
state, which carries an excess mortality rate of 2.25 %
annually but is often considered a pre-COPD state. The
model was run over a time horizon of 10 years in order to
compare with the published data for the annual rate of
FEV1 decline. The simulated mean decline in FEV1 is
found to be marginally higher (27 ml/year [95 % CI
26.1–28] vs. 24 ml/year), which could be due to the higher
proportion of smokers generated in the co-variance matrix
(64 %) compared with the OLIN study (46 %) [36].
The validation with the four studies found the model to
have generally good predictive ability, although some
inputs, such as mortality and SGRQ, could benefit from
further research. However, the overall validation yielded a
good degree of external validity. It also allowed for
refinement of the model through the addition of a no
treatment arm.
5 Discussion
To our knowledge, this is the first COPD model featuring
micro-simulation methods that allow users to incorporate
treatment switches into their analyses. We also aimed to
circumvent some of the restrictions arising from the
rigidity of set health states. These changes allow modelling
that both describes COPD disease progression in a more
accurate way and allows alignment with different treatment
guidelines where treatment switches are recurrent. In the
absence of a clear standard algorithm for determining
treatment switches, the current model triggers are based on
clinical practice as obtained from a UK physician.
Further accuracy was achieved through access to three
COPD clinical trials [22–24] that allowed the pooling of
patient-level data. This allowed the construction of a co-
variance matrix to randomly generate patients with char-
acteristics of actual COPD patients. While the inclusion/
exclusion criteria of these trials impose certain restrictions
on the generalizability of the results, it is a notable
improvement from randomly generating patient character-
istics independently. If the model should be used to study a
particular type of COPD patient population, having patient-
level data corresponding to that population would be an
advantage, but the use of this default matrix ensures that
the basic relationships between gender, age, height,
smoking status and FEV1 levels are maintained.
The current model settings mean that the model is
heavily reliant on lung function as the driver. This is a
reasonable and historically accepted framework for COPD
modelling, especially as spirometry is the standard clinical
2 The FEV1 boost was not reported in the original publication [17].
However, the authors reported a graph with the mean change in FEV1
where a very small initial boost was observed in the placebo arm.
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endpoint included in most clinical trials. However, when
exploring the determinants of treatment initiation and
switching for the UK practice, it was clear that lung
function measurements are secondary considerations:
breathlessness, cough, exacerbations and impact on a
patient’s QOL are more likely to be triggers for treatment
switch. For this reason, the model is able to accommodate
data on HR-QOL, SGRQ, TDI and history of exacerbations
to ensure a more accurate alignment with actual clinical
practice. The constraint here is on the lack of longitudinal
data around these outcomes measures. In some areas, such
as history of exacerbation, research may be forthcoming to
allow a more evidence-based approach to mapping the risk
of a recurrent exacerbation.3 In other areas, real-world
evidence needs to be collected to understand the long-term
consequences of treating certain COPD symptoms.
The results of testing published data in the model
highlighted some discrepancies across trial validation.
Although the model produced mortality rates that were
acceptable compared with the UPLIFT trial, they appeared
higher for TORCH. The difference between these results
may indicate that COPD-related mortality rates need to be
further refined according to GOLD stages or independently
of GOLD stages.
While this model has endeavoured to be comprehensive
in the description of COPD, as a multi-factorial disease
there are still areas that could be included in the model.
Examples of these are co-morbidities such as myocardial
infarction triggered by a severe exacerbation. The intention
and scope of this study, however, was to focus on the
disease progression of COPD and the impact of pharma-
ceutical interventions. Decline in TDI and SGRQ was also
assumed to be independent of patient characteristics. To
include such co-morbidities would first require that all such
relationships be documented with risk probabilities and
would widen the scope considerably to evaluate the disease
on a holistic population level.
The model also has the potential to step further away
from the GOLD-based disease severity classification,
which has recently been acknowledged as inadequate to
wholly capture the complexity of COPD. This requires
more research to quantify the relationship between lung
function decline, symptoms and HR-QOL as well as the
impact of pharmaceutical interventions on them over a
longer period of time. These research needs must be met by
both changes in RCT design and comprehensive post-
marketing observational studies.
In spite of these potential limitations, the simulation-
based model has shown good predictive ability in the
external validity testing we conducted. The model was able
to replicate the results of published clinical trials and
studies within reasonable ranges of acceptability. It has
also highlighted areas of COPD clinical research that could
benefit from more work to refine this model.
6 Conclusion
The micro-simulation model is a flexible approach for
modelling COPD that allows consideration of complex
COPD treatment pathways. The model was found to be
generally robust in terms of predicting clinical outcomes of
published studies when tested against other studies. It has
significant potential as a tool for supporting future COPD
treatment positioning decisions as well as to inform the
development of policies, guidelines or cost-effectiveness
analyses.
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